Amicus Therapeutics
Clinical trials sponsored by Amicus Therapeutics, explained in plain language.
Amicus Therapeutics
FOLD
NASDAQ
A biotech company developing treatments for rare diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for fabry patients with kidney failure: drug dosing study underway Results expected Dec 2026 (estimated)
- New hope for kids with pompe: enzyme combo trial underway Results expected Mar 2027 (estimated)
- New drug combo hopes to tame rare muscle disease in kids Results expected Jul 2027 (estimated)